Aethlon medical announces financial results for the fiscal first quarter ended june 30, 2024 and provides corporate update

Received two australian ethics committee approvals for a safety, feasibility, and dose finding study of aethlon's hemopurifier® in patients with solid tumors not responding to anti-pd-1 antibodies; expects to open patient enrollment in october of 2024 achieved significant 24% reduction in fiscal first quarter operating expenses compared to the same period in 2023 conference call to be held today at 4:30 p.m. et san diego , aug. 14, 2024 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal first quarter ended june 30, 2024 and provided an update on recent developments.
AEMD Ratings Summary
AEMD Quant Ranking